Switch to:
More From Other Websites
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Jul 22 2014
Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock Jul 21 2014
BUZZ-U.S. Stocks on the Move-Isle of Capri, Intercloud, Rent-A-Center Jul 11 2014
Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer... Jul 08 2014
Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme Jun 25 2014
Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference Jun 17 2014
Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th... Jun 15 2014
Halozyme Therapeutics (HALO) In A Perilous Reversal Jun 13 2014
Halozyme Therapeutics upgraded by UBS Jun 12 2014
The Zacks Analyst Blog Highlights: Clovis, Biogen, Halozyme, Ariad and Chart Industries Jun 12 2014
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning Jun 12 2014
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted Jun 11 2014
Today's Perilous Reversal Stock: Halozyme Therapeutics (HALO) Jun 06 2014
Halozyme Therapeutics, Inc. (HALO) in Focus: Stock Surges 12.00% Jun 06 2014
Halozyme Study Clinical Hold Lifted by FDA Jun 05 2014
Shares Of Halozyme Up 14% Following FDA Removal Of Hold On PEGPH20 Jun 05 2014
Why Halozyme Therapeutics (HALO) Stock Is Spiking Today Jun 05 2014


Add Notes, Comments or Ask Questions

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide